Bausch & Lomb Incorporated
Trial Pipeline
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
NCT07168902
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
NCT07128628
IC-8 Apthera IOL New Enrollment Post Approval Study
NCT06060041
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
NCT06978244
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
NCT06333015
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
NCT06565650
Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
NCT05264623
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
NCT07054606
Orientation Characteristics of Daily Disposable Toric Contact Lenses
NCT06069609
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
NCT05815758
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
NCT05591755
Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
NCT05129124
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
NCT04140227
Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to Dailies Total 1, Precision 1 and Biotrue ONEday Lenses
NCT04555031
Safety and IOP-Lowering Effects of WB007
NCT04149899
A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop
NCT04175340
Product Performance of a New Silicone Hydrogel Contact Lens
NCT04901897
A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Contact Lens
NCT04158466
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
NCT03896633
Clinical Study of Approved Contact Lenses
NCT03351101
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01749930
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT01591161
Evaluation of Ocular Comfort With ISTA Tears vs Systane
NCT01650584
A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens
NCT01412983
A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens
NCT01416142
Safety and Efficacy of a Contact Lens for Daily Disposable Use
NCT01365039
Evaluation of Two Daily Disposable Contact Lenses.
NCT01300065
A Study to Evaluate a New Silicone Hydrogel Contact Lens
NCT01309893
Evaluation of a New Silicone Hydrogel Contact Lens
NCT01309880
A Study to Evaluate the Performance of Two Designs of Soft Toric Lenses
NCT01309867
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
NCT01277341
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
NCT01230125
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
NCT01107405
Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
NCT01060072
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
NCT00770133
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
NCT00972777
Study of T-PRED(TM) Compared to Pred Forte(R) II
NCT00854061
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
NCT00699153
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
NCT00667004
Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution
NCT00636363
Efficacy and Safety of Bromfenac Ophthalmic Solution
NCT00585975
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
NCT00441883
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
NCT00424398
Pediatric Zylet Safety and Efficacy Study
NCT00420628
A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)
NCT00347594
A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia
NCT00348205
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
NCT00198510
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 40 |
| Phase 3 | 11 |
| Phase 4 | 3 |
Therapeutic Areas
What the Pipeline for Bausch & Lomb Incorporated Shows
According to the ClinicalTrials.gov registry, Bausch & Lomb Incorporated is linked to 78 US clinical trials across every stage of research activity. Of those, 34 studies are currently recruiting — about 44% of the sponsor's indexed portfolio — and 40 are already marked complete, representing roughly 51% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Bausch & Lomb Incorporated reports 14 late-stage studies (Phase 3 and Phase 4 combined) and 43 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Bausch & Lomb Incorporated is Myopia with 9 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.